CSL is a century-old company and a darling among healthcare stocks, having delivered a 15% annual return over the past 10 years.
Currently, investors are spooked by three risks that are getting lots of attention.
Risk 1: Weight-loss drugs
Ozempic improves glycaemic control and can be used 'off label' to assist weight loss.
While the drug has been around for years, it's making headlines because researchers are finding new applications for it and easier ways to administer it.
The risk that Ozempic-like drugs, known as GLP-1 agonists, pose to CSL can be split into broad and narrow effects.
On the broad side, Ozempic helps people lose weight by reducing appetite. Ozempic is currently very expensive, but we can imagine a future where the government subsidises the drug as a way to improve the population's overall health and take pressure off stressed healthcare budgets.
The relevance to CSL is that its sprawling network of plasma collection centres tends to focus on lower-income neighbourhoods.
However, individuals with lower incomes also face a higher risk of being overweight, so this demographic may benefit from Ozempic disproportionately.
If people on Ozempic spend less on food, and their discretionary incomes subsequently rise, the pool of willing plasma donors may decline, or CSL may need to increase donor fees to compensate.
We consider this scenario unlikely, but Ozempic could disrupt some of CSL's products directly, including in its Vifor division - chiefly iron and other therapies used by patients with chronic kidney disease (CKD) and its nephrology and cholesterol drugs.
Denne historien er fra December/January 2023-utgaven av Money Magazine Australia.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra December/January 2023-utgaven av Money Magazine Australia.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
An outrageous, beautiful monopoly
Telstra's mobile business is a cash machine with few competitors, giving it the highest returns in the world.
Drop the anchor to judge value
Buying and selling decisions should be based on where a stock price is going, not where it has been.
Powering the AI boom
Beyond the software and chipmakers, where will the energy come from?
Get into life
Tucked inside super are products that can protect you from life's inevitable uncertainties.
Paths to home ownership
Taking the road less travelled can sometimes deliver unexpected benefits.
Sold! Quick ways to add value
Small, strategic changes can have a big impact on the look and feel of your home. And get you a better price on auction day.
Money lessons the kids need to know
Your children can learn a lot from your past money mishaps. Here are eight financial conversations I have had with mine.
Property-investing rules: are they likely to change?
The pressure for the government to curb the tax benefits of tax concessions, such as negative gearing and the capital gains tax discount, is unrelenting. Most recently, independent senators David Pocock and Jacqui Lambie proposed five options for paring back investment property tax concessions, with savings to the Federal budget of up to $60 billion over the next decade.
What's love got to do with it?
A rollercoaster of emotions could be driving poor crypto behaviour.
Are we ready to be cash-free?
Saying goodbye to our piggy banks too soon could leave small businesses in the dark when problems arise.
